DIS P. 01/03 2012 602 437 0765 | 126/99 Eren



NGN TOUR 

TO: Klac/d

FAX NUMBER:

RE: MISAdun Wistration

66/52/01 DATE:

NUMBER OF PAGES:

0

I


From the desk of...

85040 Agency William A. Wright Program Manager/RAM/ 4814 South 40th Street Fax: (602) 437-0705 (602) 255-4845 ext. 227 Phoenix, Az Arizona Radiation Regulator

L. Bolling:

misalministr

RECEIVED AREA



## SAMARITAN HEALTH SYSTEM

October 12, 1999

Dan Kuhl Arizona Radiation Regulatory Agency 4814 South 48<sup>th</sup> Street Phoenix, AZ 85040

RE: Possible Misadministration, ARRA License 7-56

Dear Mr. Kuhl,

Good Samaritan Regional Medical Center is participating in the FDA-approved "INHIBIT" trial to prevent restenosis for patients with prior cardiac-stent implant. This trial, sponsored by the Guidant Cooperation, is a double-blind, sham-controlled study, in which the patients are randomly assigned to one of the two groups. One group will receive 20 Gy to 1 mm into the coronary artery wall and the other group will only receive "sham" wire treatment (0 Gy). Within GSRMC, only physicists and the radiation oncologists know whether a patient has actually received the radiation treatment. Cardiologists and patients do not know whether the wire introduced into the patient is the "active wire" or the "dummy wire". All patients have been informed about this study and signed a consent form. Patients are to be followed-up, including angiogram at 9 months after the procedure.

Our intravascular brachytherapy (IVBT) unit, made by Nucletron, was delivered at the end of the August. Brad Bisson, the clinical research coordinator from Guidant, was here for about a week to provide training and oversee the first 5 studies on September 1, 1999.

On September 22, 1999, during case 138-1406, we felt there was some discrepancy between our observation and the treatment record from the IVBT unit. This patient was randomized to receive radiation treatment and the machine was programmed correctly to deliver radiation treatment. However the radiation oncologist noticed that, during studywire extension, the wheel associated with "sham wire" or the dummy source was turning. Since our IVBT unit employed a P-32 source, the survey meter was not useful to detect the beta source inside the patient. During the source retraction, several people witnessed the turning of the black "dummy" wheel and the survey meter did not register any radiation during the retracting process. We did notice that there was an interruption with error code 1514 at one minute into the treatment.

After case 138-1406, we had another case 138-1407 scheduled. Between cases, we were trying to contact the Guidant Corporation and test the IVBT unit. The unit tested out OK and the second case was completed successfully.

Page 2

RM 7-56: IVBT event reporting

The next day, we sent computer back-up tape and all relevant documents to Guidant for evaluation. On 10/5/99, I received an e-mail back from Nucletron, via Guidant, that confirmed our observation that only the check source was used for treatment from the "first analysis on the data". I immediately provided all information to ARRA via e-mail regarding this unusual event.

I would like to point out a few things regarding this case:

- 1. This is an experimental procedure approved by the FDA. Since this is a randomized study, some patient may not receive radiation treatment.
- 2. There was no harm at all to the patient in this case 138-1406. There was a 50% chance that the patient may receive no radiation by randomization.
- 3. All records from the IVBT unit showed that the patient was treated correctly with radiation with no misadministration.
- 4. All information I received from the Guidant/Nucletron was preliminary information. With further analysis and testing, it is possible that the final result may be different and I'll keep you informed.
- 5. Since this is a randomized study, the patient and the cardiologist are not supposed to know whether this patient received radiation treatment or sham treatment.

  Since there was no harm to the patient and informing patient and the cardiologist may jeopardize the randomized study, the patient and the cardiologist are not informed about this possible misadministration. (R12-1-708 A.1)

If you need additional information, please call me at (602) 239-2226. Thank you for your assistance.

Sincerely,

David Liu, Ph.D., RSO

Copy: Brad Bisson, Guidant Co.

Susan Dimpfel Dr. Lucas